The addition of bevacizumab to temozolomide-based chemotherapy was also associated with higher rates of grade 3 or higher thrombocytopenia and anemia.
According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.
A phase 0 study of ribociclib in patients with recurrent glioblastoma seeks to inform the feasibility of the use of CDK 4/6 inhibitors for deadly brain tumors.
For specific subsets of patients with intermediate-risk neuroblastoma, an algorithm successfully reduced treatment while maintaining survival outcomes.
Survivors of childhood low-grade gliomas treated with radiotherapy have poorer neuropsychological and socioeconomic-status (SES) outcomes.
A primary outcome measure for phase 1 of the trial is determining the safety of oral LOXO-292.
Computer-assisted diagnosis (CAD) can help physicians detect growth of low-grade gliomas.
Entrectinib showed activity and appeared to be safe in pediatric patients with recurrent or refractory solid tumors harboring NTRK1/2/3, ROS1, or ALK aberrations.
AbbVie has halted enrollment in all ongoing studies of depatuxizumab mafodotin, after an Independent Data Monitoring Committee (IDMC) recommended a phase 3 study of the treatment be stopped due to a lack of survival benefit.
New studies in glioblastoma highlight how PD-1 inhibitors could simultaneously prompt an immune response and steer the selection of tumor clones that evade immune recognition.
